US · INM
InMed Pharmaceuticals Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Vancouver, BC V6C 1B4
- Website
- inmedpharma.com
Price · as of 2025-06-30
$0.71
Market cap 1.54M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $17.15 | +2,300.28% |
| Intrinsic Value(DCF) | $6.40 | +795.73% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.00 | $10,612.90 | |||
| 2012 | |||||
| 2013 | |||||
| 2014 | $4,455.00 | ||||
| 2015 | $2,475.00 | ||||
| 2016 | $1,204.50 | ||||
| 2017 | $4,405.50 | ||||
| 2018 | $9,735.00 | ||||
| 2019 | $4,785.00 | ||||
| 2020 | $2,057.50 | ||||
| 2021 | $1,045.00 | ||||
| 2022 | $220.40 | $0.00 | $0.00 | ||
| 2023 | $17.20 | $5,003.93 | $283,723.20 | $0.00 | $0.00 |
| 2024 | $5.34 | $22.29 | $62.83 | $0.00 | $0.00 |
| 2025 | $2.11 | $17.15 | $9.56 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates InMed Pharmaceuticals Inc.'s (INM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $17.15
- Current price
- $0.71
- AI upside
- +2,300.28%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.40
+795.73% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INM | InMed Pharmaceuticals Inc… | $0.71 | 1.54M | +2,300% | +796% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| BIVI | BioVie Inc. | $1.38 | 10.41M | — | — | — | — | -0.15 | 0.14 | — | 0.86 | — | 0.14 | 0.00% | — | — | -101.64% | 8838.56% | -75.01% | 0.02 | -54.30 | 9.10 | 8.64 | 1.01 | -8341.00% | — | -3192.00% | -740.10% | -8.36 | 9307.74% | 0.00% | 0.00% | 0.00% | 0.81 | 0.77 | — | -24.00 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| ESLA | Estrella Immunopharma, In… | $1.22 | 51.28M | — | — | — | — | -4.10 | 252.14 | — | -3.99 | — | 252.14 | 0.00% | — | — | — | — | — | 0.00 | — | 0.55 | 0.31 | 0.10 | — | — | — | -21.08% | -2.55 | — | 0.00% | 0.00% | 1.57% | -3.99 | -4.62 | — | -13.22 |
| GLMD | Galmed Pharmaceuticals Lt… | $0.61 | 3.35M | — | — | — | — | -0.23 | 0.11 | — | 1.83 | — | 0.11 | 0.00% | — | — | -49.77% | -552.15% | -42.80% | 0.00 | -418.53 | 7.42 | 7.15 | 0.63 | -7302.00% | — | -419.00% | -334.59% | -2.71 | -517.15% | 0.00% | 0.00% | 104.25% | 2.16 | 2.31 | — | -14.90 |
| GNPX | Genprex, Inc. | $2.00 | 3.26M | — | — | — | — | -0.06 | 0.84 | — | 0.01 | — | 0.84 | 0.00% | — | — | -467.24% | -6073.62% | -285.38% | 0.00 | — | 0.83 | 0.64 | 0.08 | -7633.00% | — | -3088.00% | -1259.09% | -6.85 | -4919.06% | 20346.13% | -1312.70% | 20346.13% | 0.01 | 0.01 | — | -69.29 |
| GRI | GRI Bio, Inc. | $2.55 | 229.07K | +6,695% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| JAGX | Jaguar Health, Inc. | $0.89 | 1.93M | +7,724% | +550% | — | — | -0.11 | 0.58 | 0.36 | -0.89 | — | -0.38 | 83.27% | -263.76% | -329.30% | -637.50% | -86.37% | -74.93% | 5.01 | -133.47 | 1.63 | 0.49 | -0.78 | -9513.00% | 1975.00% | -1091.00% | -697.04% | -1.49 | -82.96% | 0.00% | 0.00% | 49.45% | -1.06 | -1.11 | 2.80 | -10.43 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| SILO | Silo Pharma, Inc. | $0.37 | 2.92M | +5,090% | +86% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
- CEO
- Eric A. Adams Chem.
- Employees
- 13
- Beta
- 0.40
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.40 ÷ $0.71) − 1 = +795.73% (DCF, example).